Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.37)
# 327
Out of 5,152 analysts
118
Total ratings
52.29%
Success rate
18.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Maintains: Buy | $46 → $58 | $44.53 | +30.25% | 4 | Mar 4, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $256.29 | +10.81% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $59.59 | +44.32% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $29.59 | +52.10% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $5.46 | +28.32% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $11.91 | +67.93% | 1 | Feb 11, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $64 → $52 | $21.17 | +145.63% | 4 | Jan 5, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $3.07 | +95.44% | 4 | Dec 12, 2025 | |
| PHVS Pharvaris | Maintains: Buy | $32 → $39 | $25.30 | +54.18% | 1 | Dec 4, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $28 → $43 | $25.88 | +66.15% | 8 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $15.59 | +21.87% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $6.82 | +340.21% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $11.61 | +718.26% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $74.10 | +24.16% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $38.21 | +177.42% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $8.23 | +21.51% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $13.10 | +6.87% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $456.50 | +19.61% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $14.89 | +235.80% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $26.32 | +109.01% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.79 | +374.93% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $10.43 | +62.99% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.33 | +4.71% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $56.16 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.44 | +327.93% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.90 | +464.10% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.23 | +1,200.45% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $317.04 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $4.41 | +534.92% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $13.08 | +52.91% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $32.77 | +275.34% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $25.50 | +111.76% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.12 | +5,257.14% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.17 | - | 3 | Jun 26, 2017 |
Maze Therapeutics
Mar 4, 2026
Maintains: Buy
Price Target: $46 → $58
Current: $44.53
Upside: +30.25%
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $256.29
Upside: +10.81%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $59.59
Upside: +44.32%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $29.59
Upside: +52.10%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $5.46
Upside: +28.32%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $11.91
Upside: +67.93%
Ultragenyx Pharmaceutical
Jan 5, 2026
Maintains: Buy
Price Target: $64 → $52
Current: $21.17
Upside: +145.63%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $3.07
Upside: +95.44%
Pharvaris
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $25.30
Upside: +54.18%
Centessa Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $28 → $43
Current: $25.88
Upside: +66.15%
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $15.59
Upside: +21.87%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $6.82
Upside: +340.21%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $11.61
Upside: +718.26%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $74.10
Upside: +24.16%
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $38.21
Upside: +177.42%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $8.23
Upside: +21.51%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $13.10
Upside: +6.87%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $456.50
Upside: +19.61%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $14.89
Upside: +235.80%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $26.32
Upside: +109.01%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.79
Upside: +374.93%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $10.43
Upside: +62.99%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.33
Upside: +4.71%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $56.16
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.44
Upside: +327.93%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.90
Upside: +464.10%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.23
Upside: +1,200.45%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $317.04
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $4.41
Upside: +534.92%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $13.08
Upside: +52.91%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $32.77
Upside: +275.34%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $25.50
Upside: +111.76%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.12
Upside: +5,257.14%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $27.17
Upside: -